John C. Williams

Capital Markets

John advises on various capital markets transactions, from IPOs and direct listings to follow-on offerings. His experience includes representing:

• Revolution Medicines in its US$2.2 billion equity and convertible notes offering, as well as its IPO and multiple follow-on and at-the-market offerings
• Ascendis Pharma in the first listing of Danish ordinary shares on a US stock exchange (Nasdaq), as well as its IPO, follow-on offerings, and royalty financings
• Ceribell in its IPO
• IDEAYA Biosciences in its follow-on offerings and at-the-market offerings
• Underwriters in the HashiCorp IPO
• Financial advisors in the Asana direct listing
• Aligos Therapeutics in its IPO, and follow-on offering and PIPE transactions
• Initial purchasers in the Slack Technologies convertible notes offering
• Financial advisors in the Slack Technologies direct listing
• Codexis in its at-the-market offering
• Underwriters in the IPO of Harpoon Therapeutics
• Ardelyx in its PIPE transactions and at-the-market offerings
• Arcus Biosciences in its follow-on offerings and at-the-market offerings
• CytomX Therapeutics in its follow-on offerings, PIPE transaction and at-the-market offerings
• Achaogen in its follow-on offerings, at-the-market equity offerings, and PIPE transaction
• Initial purchasers in BioMarin Pharmaceutical convertible notes offering
• PDF Solutions in its follow-on offering
• Prothena Corporation in its follow-on offering
• e.l.f. Beauty in its public offering by selling stockholders
• Integrated Device Technology in its convertible notes offering
• Relypsa in its IPO, follow-on offering, and at-the-market equity offerings
• Initial purchasers in Salesforce.com convertible notes offering
• Underwriters in the IPO and follow-on offering of KaloBios Pharmaceuticals
• OncoMed Pharmaceuticals in its IPO and at-the-market equity offering
• Corcept Therapeutics in its follow-on offering
• Sarepta Therapeutics in its follow-on offering and its at-the-market equity offering
• Zosano Pharma in its follow-on and at-the-market offerings

Company Representation and Venture Financings

John represents public and private companies in general corporate matters, public company reporting, venture capital financings, and strategic transactions. His clients include:

• 4D Molecular Therapeutics (public; biotech)
• Aligos Therapeutics (public; biotech)
• Ascendis Pharma (public; biotech)
• Arcus Biosciences (public; biotech)
• Ardelyx (public; biotech)
• Azora Therapeutics (private; biotech)
• Ceribell (public; medical device)
• Codexis (public; enzyme engineering)
• CytomX Therapeutics, Inc. (public; biotech)
• Extreme Networks (public; tech)
• Fandom (private; tech)
• IDEAYA Biosciences (public; biotech)
• Intuitive Surgical (public; medical device)
• National Resilience (private; biomanufacturing)
• Revolution Medicines (public; biotech)

Mergers and Acquisitions and Activism Defense

John has advised on the following M&A and activism defense matters:

• e.l.f. Beauty (public) in its cooperation agreement with Marathon Partners
• Fandom (private) in acquisition of Huddler
• Mirna Therapeutics (public) in its reverse merger transaction with Synlogic
• OpenTable (public) in acquisition of Foodspotting
• Pearl Therapeutics (private) in its sale to AstraZeneca
• Relypsa (public) in its sale to Galenica Group
• Revolution Medicines (public) in its acquisition of EQRx